Vinblastine in the Treatment of Children and Adolescents with Refractory Immune Thrombocytopenia
May 2011
in “
American Journal of Hematology
”
TLDR Vinblastine can help treat childhood ITP but may cause reversible side effects.
The study assessed Vinblastine (VBL) as a second-line treatment for 17 children and adolescents with refractory immune thrombocytopenia (ITP), showing an initial response in 11 patients and sustained response in 8 during maintenance. While VBL effectively increased platelet counts and controlled bleeding, side effects like neuropathic pain were noted in 11 patients but were reversible. The study concluded that VBL could be a viable option for treating childhood ITP, though further research was necessary to fully evaluate its efficacy.
